Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
466 Leser
Artikel bewerten:
(2)

ACEGID and Illumina to Increase Africa's Genomics Capacity through Establishment of a Joint Training Academy

NORTHAMPTON, MA / ACCESSWIRE / April 5, 2023 / Illumina

Originally published on LinkedIn

The African Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer's University, announced that it will collaborate with Illumina, a global leader in sequencing and array-based technologies, on a joint workforce development training academy, with the objective of increasing Africa's genomics capacity.

In February, @ACEGID and Illumina signed a memorandum of understanding, and will work towards an agreement to leverage the existing pathogen Genomics and Bioinformatics Bootcamp programme at ACEGID, to set up an ambitious training programme targeting 1,000 young African researchers and scientists in Genomics and Bioinformatics between March 2023 and December 2025. This will significantly increase the supply of qualified technical workforce for next-generation sequencing wet lab management, bioinformatics, big data analytics and advanced artificial intelligence/machine learning applications.

The objective is to establish a Genomics and Bioinformatics training Academy within ACEGID at Redeemer's University, Ede, Nigeria. Illumina and ACEGID will also explore the implementation of a "mobile lab-in-container" that will enable real-time and on-the-move sequencing for outbreak responses in West Africa. This new programme fits into ACEGID's SENTINEL pandemic preparedness and response programme of identifying pathogens with pandemic potentials in the field before they can wreak havoc.

"This new cooperation with Illumina is in complete alignment with the mandate of ACEGID, which is to train a critical mass of young African scientists that will use genomics tools and technologies to address public health challenges in Africa," said Prof. Christian Happi, the Director of ACEGID.

"We share a collective goal with ACEGID of extending the reach of genomic technologies and their impacts for patients," said Susan Tousi, Chief Commercial Officer of Illumina. "Africa has the greatest genetic diversity of any continent, and this opportunity to contribute to the future of accessing that diversity for the benefit of human health is one Illumina is proud to support."

The two organizations will also work towards collaborations for pharmacogenomics (the study of how genes affect a person's response to drugs) and precision oncology (the treatment of cancers based on the specific genes that cause cancerous growth in a patient) for Africans.

"Making precision medicine a reality for all populations is core to Illumina's mission to improve human health by unlocking the power of the genome," said Illumina Chief Executive Officer Francis deSouza. "Today, only 2% of genomic data comes from African individuals, and we're committed to changing that. It begins with empowering local scientists and researchers with tools, resources, and training on the power of genomics. Our work with Prof. Happi and ACEGID builds on our goal to rapidly expand sequencing capabilities and capacity for all people in Africa, and will impact every area of precision medicine, from drug development to cancer screening, therapy selection and monitoring."

Prof. Happi added, "What is unique about this cooperation is that both Illumina and ACEGID are agreeing to put in place the necessary infrastructure for training in genomics, research and innovation that is going beyond infectious diseases to also address the issues of non-communicable diseases."

This cooperation aims to be a landmark in the African genomics and public health space; addressing the needs for both human resources development and infrastructure for proper training to enable increased capacity for genomics on the continent.

'Fikayo Oyewale

Scientific Communications Officer, ACEGID

Illumina, Wednesday, April 5, 2023, Press release picture

View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com.

Contact Info:
Spokesperson: Illumina
Website: https://www.3blmedia.com/profiles/illumina
Email: info@3blmedia.com

SOURCE: Illumina

View source version on accesswire.com:
https://www.accesswire.com/747776/ACEGID-and-Illumina-to-Increase-Africas-Genomics-Capacity-through-Establishment-of-a-Joint-Training-Academy

© 2023 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.